´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11 |
|
´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11 ±³À°ÁÖÁ¦ : The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium ÁÖÃÖ±â°ü : ´ëÇÑÀü¸³¼±ÇÐȸ À̸ÞÀÏ : gaonpco@gaonpco.com ±³À°Á¾·ù : ºñ´¢ÀÇÇаú, ÀÇÇб³À° Âü¼®¿¹»óÀÎ : 100¸í Áö¿ª : ¼¿ïƯº°½Ã ¼¼ºÎ¼ö°·á : 30,000¿ø ºñ°í »çÀüµî·Ï Àü¹®ÀÇ 2¸¸¿øÀü°øÀÇ 1¸¸¿ø ÇöÀåµî·ÏÀü¹®ÀÇ 3¸¸¿øÀü°øÀÇ 2¸¸¿ø
±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°È¦ 13:00~13:15 Locally advanced cancer (very high-risk or N1) in the PSMA era Á¶Á¤±â(ÇѾçÀÇ´ë) Åä·Ð 05¿ù 11ÀÏ ±Ý°È¦ 13:15~13:45 Panel discussion ±èÅûó(°í½ÅÀÇ´ë) ±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°È¦ 13:45~14:00 Tactics of ADT administration - continous vs. intermittent ÀÌÇйÎ(¼¿ïÀÇ´ë) Åä·Ð 05¿ù 11ÀÏ ±Ý°È¦ 14:00~14:30 Panel discussion ±èº´ÈÆ(°è¸íÀÇ´ë) ±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°È¦ 14:50~15:05 Treatment choice following doublet/triplet therapy for mHSPC ¹ÚÁ¾¿í(¿øÀڷº´¿ø) Åä·Ð 05¿ù 11ÀÏ ±Ý°È¦ 15:05~15:35 Panel discussion Á¶¹®±â(¿øÀڷº´) ±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°È¦ 15:35~15:50 The positioning of olaparib/abiraterone within mCRPC sequencing ÇÑÇöÈ£(¿¬¼¼ÀÇ´ë) Åä·Ð 05¿ù 11ÀÏ ±Ý°È¦ 15:50~16:20 Panel discussion Á¤Àç½Â(ÀÎÁ¦ÀÇ´ë) ±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°È¦ 16:20~16:35 Apalutamide rash prevalence study: Updated results ±è¿øÅÂ(ÃæºÏÀÇ´ë) ±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°È¦ 16:35~16:50 PSMA theranostics for prostate cancer ¼¹Î¼®(¼¿ïÀÇ´ë)
|
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|